Results 201 to 210 of about 26,462 (230)

P2Y12 receptor residues crucial for thrombosis regulation

Journal of Molecular Recognition, 2023
AbstractThrombosis, or the formation of blood clots, can lead to serious medical conditions such as stroke, heart attack, and deep vein thrombosis. The purinoreceptor P2Y12 plays a critical role in the thrombotic pathway and is targeted for therapy to prevent clot formation.
openaire   +2 more sources

The role of P2Y12 receptor in ischemic stroke of atherosclerotic origin

Cellular and Molecular Life Sciences, 2018
Atherosclerosis is a chronic and progressive disease of the arterial walls and a leading cause of non-cardioembolic ischemic stroke. P2Y12 is a well-recognized receptor that is expressed on platelets and is a target of thienopyridine-type antiplatelet drugs.
Ying, Gao, Cheng, Yu, Shulan, Pi, Ling, Mao, Bo, Hu   +4 more
openaire   +2 more sources

The P2Y12 receptor: no active metabolite, no party

Nature Reviews Cardiology, 2009
Poor responders to clopidogrel have low levels of circulating active metabolite. However, in vitro experiments have shown that blood platelets from poor responders are fully inhibited by the active metabolite of this prodrug. Impaired platelet inhibition reflects inadequate plasma levels of active metabolites, and not differences in platelet P2Y12 ...
openaire   +1 more source

Overview of pleiotropic effects of platelet P2Y12 receptor inhibitors

Thrombosis and Haemostasis, 2014
SummaryDual antiplatelet therapy consisting of one of the P2Y12 receptor inhibitors in conjunction with aspirin is the mainstay of treatment for patients with acute coronary syndromes (ACS) and those undergoing percutaneous coronary interventions (PCI).
Adamski, P., Kozinski, M., Ostrowska, M., Fabiszak, T., Navarese, E.P., Navarese, E.P., Paciorek, P., Grzesk, G., Kubica, J.   +8 more
openaire   +2 more sources

The P2Y12 receptor regulates microglial activation by extracellular nucleotides

Nature Neuroscience, 2006
Microglia are primary immune sentinels of the CNS. Following injury, these cells migrate or extend processes toward sites of tissue damage. CNS injury is accompanied by release of nucleotides, serving as signals for microglial activation or chemotaxis. Microglia express several purinoceptors, including a G(i)-coupled subtype that has been implicated in
Sharon E, Haynes, Gunther, Hollopeter, Guang, Yang, Dana, Kurpius, Michael E, Dailey, Wen-Biao, Gan, David, Julius   +6 more
openaire   +2 more sources

Structure, Pharmacology and Roles in Physiology of the P2Y12 Receptor

2017
P2Y receptors are G-protein-coupled receptors (GPCRs) for extracellular nucleotides. The platelet ADP-receptor which has been denominated P2Y12 receptor is an important target in pharmacotherapy. The receptor couples to Gαi2 mediating an inhibition of cyclic AMP accumulation and additional downstream events including the activation of ...
openaire   +2 more sources

The influence of variation in the P2Y12 receptor gene on in vitro platelet inhibition with the direct P2Y12 antagonist cangrelor

Thrombosis and Haemostasis, 2010
SummaryNovel P2Y12 inhibitors are in development to overcome the occurrence of atherothrombotic events associated with poor responsiveness to the widely used P2Y12 inhibitor clopidogrel. Cangrelor is an intravenously administered P2Y12 inhibitor that does not need metabolic conversion to an active metabolite for its antiplatelet action, and as a ...
Bouman, HJ, van Werkum, JW, Rudez, Goran, Leebeek, Frank, Kruit, A, Hackeng, CM, van den Berg, JM, de Maat, Moniek, Ruven, HJT   +8 more
openaire   +2 more sources

Ticagrelor: Effects Beyond the P2Y12 Receptor.

Interventional cardiology clinics, 2017
Platelet P2Y12 receptor inhibitors are crucial in the treatment of patients with acute coronary syndrome or undergoing percutaneous coronary intervention. Ticagrelor is a reversibly binding, potent oral P2Y12 inhibitor that also is a weak inhibitor of the equilibrative nucleoside transporter-1 pathway for cellular adenosine uptake.
Sumaya, W., Storey, R.F.
openaire   +1 more source

Efficacy and Safety of Ticagrelor: A Reversible P2Y12 Receptor Antagonist

Annals of Pharmacotherapy, 2010
Objective: To summarize the pharmacokinetic and pharmacodynamic properties of ticagrelor, a selective P2Y12 receptor antagonist, and evaluate its role in the treatment of patients with acute coronary syndromes (ACS). Data Sources: A literature search was conducted in MEDLINE (1966–November 2009), International Pharmaceutical Abstracts (1970–November ...
Shawn D, Anderson, Niren K, Shah, Juwon, Yim, Benjamin J, Epstein   +3 more
exaly   +3 more sources

Purinergic Receptor P2Y12-Mediated Tau Internalization in Microglia

Microglia are the resident brain macrophage cells that are involved in constant surveillance of brain microenvironment. In Alzheimer's disease, microglia get over activated upon the accumulation of Tau and amyloid-β species in the extracellular space, ultimately leading to neurodegeneration.
Hariharakrishnan Chidambaram, Smita Eknath Desale, Subashchandrabose Chinnathambi   +2 more
openaire   +2 more sources